These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26318165)

  • 41. The search for therapeutic options for Middle East Respiratory Syndrome (MERS).
    Arabi YM; Balkhy HH; Hayden FG; Hui DS; Van Kerkhove MD; Fowler RA
    J Infect Public Health; 2016; 9(3):213-5. PubMed ID: 27050470
    [No Abstract]   [Full Text] [Related]  

  • 42. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.
    Li Y; Wan Y; Liu P; Zhao J; Lu G; Qi J; Wang Q; Lu X; Wu Y; Liu W; Zhang B; Yuen KY; Perlman S; Gao GF; Yan J
    Cell Res; 2015 Nov; 25(11):1237-49. PubMed ID: 26391698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody.
    Ying T; Prabakaran P; Du L; Shi W; Feng Y; Wang Y; Wang L; Li W; Jiang S; Dimitrov DS; Zhou T
    Nat Commun; 2015 Sep; 6():8223. PubMed ID: 26370782
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia.
    Sabir JS; Lam TT; Ahmed MM; Li L; Shen Y; Abo-Aba SE; Qureshi MI; Abu-Zeid M; Zhang Y; Khiyami MA; Alharbi NS; Hajrah NH; Sabir MJ; Mutwakil MH; Kabli SA; Alsulaimany FA; Obaid AY; Zhou B; Smith DK; Holmes EC; Zhu H; Guan Y
    Science; 2016 Jan; 351(6268):81-4. PubMed ID: 26678874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The heptad repeat region is a major selection target in MERS-CoV and related coronaviruses.
    Forni D; Filippi G; Cagliani R; De Gioia L; Pozzoli U; Al-Daghri N; Clerici M; Sironi M
    Sci Rep; 2015 Sep; 5():14480. PubMed ID: 26404138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study.
    Chowell G; Abdirizak F; Lee S; Lee J; Jung E; Nishiura H; Viboud C
    BMC Med; 2015 Sep; 13():210. PubMed ID: 26336062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus.
    Chen Y; Chan KH; Kang Y; Chen H; Luk HK; Poon RW; Chan JF; Yuen KY; Xia N; Lau SK; Woo PC
    Emerg Microbes Infect; 2015 Apr; 4(4):e26. PubMed ID: 26421268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Growth and Quantification of MERS-CoV Infection.
    Coleman CM; Frieman MB
    Curr Protoc Microbiol; 2015 May; 37(1):15E.2.1-9. PubMed ID: 26344219
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea.
    Park WB; Perera RA; Choe PG; Lau EH; Choi SJ; Chun JY; Oh HS; Song KH; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Man Poon LL; Peiris M; Oh MD
    Emerg Infect Dis; 2015 Dec; 21(12):2186-9. PubMed ID: 26583829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.
    Zumla A; Azhar EI; Arabi Y; Alotaibi B; Rao M; McCloskey B; Petersen E; Maeurer M
    Int J Infect Dis; 2015 Nov; 40():71-4. PubMed ID: 26365771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-time reverse transcriptase polymerase chain reaction assays for Middle East Respiratory Syndrome.
    Douglas CE; Kulesh DA; Jaissle JG; Minogue TD
    Mol Cell Probes; 2015 Dec; 29(6):511-513. PubMed ID: 26365228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serological Evidence of MERS-CoV Antibodies in Dromedary Camels (Camelus dromedaries) in Laikipia County, Kenya.
    Deem SL; Fèvre EM; Kinnaird M; Browne AS; Muloi D; Godeke GJ; Koopmans M; Reusken CB
    PLoS One; 2015; 10(10):e0140125. PubMed ID: 26473733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease.
    Tao X; Garron T; Agrawal AS; Algaissi A; Peng BH; Wakamiya M; Chan TS; Lu L; Du L; Jiang S; Couch RB; Tseng CT
    J Virol; 2016 Jan; 90(1):57-67. PubMed ID: 26446606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge.
    Lan J; Yao Y; Deng Y; Chen H; Lu G; Wang W; Bao L; Deng W; Wei Q; Gao GF; Qin C; Tan W
    EBioMedicine; 2015 Oct; 2(10):1438-46. PubMed ID: 26629538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coronaviruses - drug discovery and therapeutic options.
    Zumla A; Chan JF; Azhar EI; Hui DS; Yuen KY
    Nat Rev Drug Discov; 2016 May; 15(5):327-47. PubMed ID: 26868298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Origin and Possible Genetic Recombination of the Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China: Phylogenetics and Coalescence Analysis.
    Wang Y; Liu D; Shi W; Lu R; Wang W; Zhao Y; Deng Y; Zhou W; Ren H; Wu J; Wang Y; Wu G; Gao GF; Tan W
    mBio; 2015 Sep; 6(5):e01280-15. PubMed ID: 26350969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease.
    Johnson RF; Via LE; Kumar MR; Cornish JP; Yellayi S; Huzella L; Postnikova E; Oberlander N; Bartos C; Ork BL; Mazur S; Allan C; Holbrook MR; Solomon J; Johnson JC; Pickel J; Hensley LE; Jahrling PB
    Virology; 2015 Nov; 485():422-30. PubMed ID: 26342468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.
    Kyratsous CA; Olson W; Stahl N
    Proc Natl Acad Sci U S A; 2015 Sep; 112(37):E5116. PubMed ID: 26318164
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.